Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.50 |
| ▸ | PRKCI | P41743 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | NRAS | P01111 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216854 | 1.00 | IRAK4 (0.50) | IRAK4PRKCIMAPK1HRH3NRAS | |
| SCHEMBL25422820 | 1.00 | IRAK4 (0.50) | IRAK4PRKCIMAPK1HRH3NRAS | |
| SCHEMBL30632323 | 1.00 | IRAK4 (0.50) | IRAK4PRKCIMAPK1HRH3NRAS | |
| SCHEMBL13326544 | 1.00 | IRAK4 (0.50) | IRAK4PRKCIMAPK1HRH3NRAS | |
| Hydrochloric Acid SCHEMBL4056190 | 0.98 | IRAK4 (0.49) | IRAK4PRKCIMAPK1HRH3NRAS | |
| Hydrochloric Acid SCHEMBL4056189 | 0.98 | IRAK4 (0.49) | IRAK4PRKCIMAPK1HRH3NRAS | |
| SCHEMBL4705576 | 0.90 | IRAK4 (0.52) | IRAK4FLT3IRAK1PRKD2RPS6KB1 | |
| SCHEMBL1088572 | 0.90 | HRH3 (0.55) | IRAK4MAPK1HRH3NOS2 | |
| SCHEMBL2351225 | 0.89 | IRAK4 (0.48) | IRAK4PRKCIFLT3IRAK1PRKD1 | |
| Hydrochloric Acid SCHEMBL1307469 | 0.88 | HRH3 (0.54) | IRAK4MAPK1HRH3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030557-B1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | IDIENCE CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-RE49338-E1 | Phthalazinone derivatives and manufacturing process thereof | IDIENCE CO., LTD. (KR) | 2022-12-20 | — | — | US | disclosed |
| US-9844550-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-12-19 | — | — | US | disclosed |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2017-06-29 | — | — | US | disclosed |
| US-9682973-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-06-20 | — | — | US | disclosed |
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, PARP1 | IRAK4 2203/4885PRKCI 2507/4885MAPK1 3527/4885 |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, NUDT5 | IRAK4 2566/4885PRKCI 2456/4885MAPK1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.